VYGR Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Voyager Therapeutics Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 7.62 USD 2.7%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast VYGR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VYGR is 18.13 USD with a low forecast of 10.1 USD and a high forecast of 31.5 USD.

VYGR Lowest Forecast

Wall Street Target

VYGR Average Forecast

Wall Street Target

VYGR Highest Forecast

Wall Street Target

33% Upside

138% Upside

313% Upside

The latest public price target was made on Jan 2, 2024 by Jim Birchenough from Wells Fargo , who expects VYGR stock to rise by 84% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Jim Birchenough Wells Fargo	14 USD Upside 84%	3 months ago Jan 2, 2024	Wells Fargo Upgrades Voyager Therapeutics (VYGR) to Overweight StreetInsider
Joon Lee Truist Financial	18 USD Upside 136%	11 months ago May 10, 2023	Voyager Therapeutics' Seasoned Management And Leading Adeno-Associated Virus Capsid Platform Impress Bullish Analyst Benzinga

Price Target	14 USD
Upside/Downside	84%

Price Target	18 USD
Upside/Downside	136%

Dyadic International Inc

413% Upside

Orthocell Ltd

50% Upside

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

8% Upside

Kinnate Biopharma Inc

9% Downside

Dyadic International Inc

413% Upside

Orthocell Ltd

50% Upside

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

8% Upside

Kinnate Biopharma Inc

9% Downside

TG Therapeutics Inc

130% Upside

Immatics NV

91% Upside

Harpoon Therapeutics Inc

8% Upside

Poseida Therapeutics Inc

570% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Voyager Therapeutics Inc's revenue is 40%. The projected CAGR for the next 3 years is -39%.

40%

-39%

5%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

2%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-45%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for VYGR is 18.13 USD with a low forecast of 10.1 USD and a high forecast of 31.5 USD.

For the last 8 years the compound annual growth rate for Voyager Therapeutics Inc's revenue is 40%. The projected CAGR for the next 3 years is -39%.

Join more than 132,000+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.